Pages

30 November 2020

The Last, ‘Ultra-Cold’ Mile for Covid-19 Vaccines

Maryn McKenna

Two vaccines are nearly here—but their unusual storage requirements could deprive the rural areas that need them most. A tech fix might be coming.

The pace of countering the coronavirus in the US is about to pick up. Two manufacturers, Pfizer and Moderna, have announced that their formulas are up to 95 percent effective at preventing Covid-19; Pfizer officials backed up their statement with a full report on their Phase III data, and one from Moderna should follow soon. On Friday, Pfizer announced that company officials are asking the Food and Drug Administration for an EUA—an emergency use authorization—a shortcut around the standard lengthy approval process. An advisory committee of the Centers for Disease Control and Prevention meets today, and another committee reporting to the FDA has scheduled a meeting to assess both formulas on December 10.

No comments:

Post a Comment